Introduction: Non-oxidized (n-ox) PTH could better reflect PTH activity. We have evaluated the evolution of n-ox PTH and intact PTH (iPTH) in hemodialyzed (HD) patients over a period of 1 year.
Material And Methods: We measured iPTH and n-ox PTH in 66 stable HD patients and we measured iPTH and n-ox PTH at baseline and after 1, 3, 6 and 12 months.
End-stage renal disease is associated with mineral and bone disorders. Guidelines recommending therapies should be based on serial assessments of biomarkers, and thus on variations (Δ), rather than scattered values. We analyzed the correlations between ΔPTH and Δbone biomarkers such as bone-specific alkaline phosphatase (b-ALP), Beta-CrossLaps (CTX), osteocalcin, intact serum procollagen type-1 N-propeptide (P1NP), and tartrate-resistant acid phosphatase 5B (TRAP-5B) at different time-points.
View Article and Find Full Text PDFIntroduction: Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend vitamin D supplementation in hemodialyzed patients to monitor 25(OH)-vitamin D 25(OH)D levels. However, patient-to-patient inconsistency can be observed in response to the treatment. In this study, we aimed to evaluate the impact of the dialysis membrane on 25(OH)D, albumin (Alb) and vitamin D-binding protein (VDBP), the major players of vitamin D transport and storage.
View Article and Find Full Text PDFBackground: Sclerostin is a potent inhibitor of bone formation, but the meaning of its serum levels remains undetermined. We evaluated the association between sclerostin levels and clinical or biological data in hemodialyzed patients (HD), notably parathormone (PTH), biomarkers of bone turnover, vascular calcifications and mortality after 2 years.
Methods: 164 HD patients were included in this observational study.